Drugs / NBI-1117570
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07288333 | Feb 2026 → Aug 2027 expected | schizophrenia | Neurocrine Biosciences | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-13 | Nxera Pharma UK Limited | Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia nxera.life ↗ |
| 2023-09-12 | Nxera Pharma UK Limited | Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults nxera.life ↗ |
| 2023-09-11 | Neurocrine Biosciences | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults gcs-web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBI-1117570 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288333 ↗ |
| Route | Oral | “Oral administration” NCT07288333 ↗ |